GLOBAL MARKETS LIVE: Boeing’s 737 Max to resume flights in Europe, Merck’s latest acquisition…
|11/23/2020 | 10:02am|
The European Aviation Safety Agency should give the green light for Boeing's 737 MAX to resume flights. We’re also talking about AstraZeneca's vaccine data, Elliott's bid for Aryzta in Switzerland and the ambitions of Zurich and Siegfried.
AstraZeneca announces an average efficacy of 70% for its Covid-19 vaccine.
The European Aviation Safety Agency (EASA) will give the green light for Boeing's 737 MAX to resume flights in European skies in January, EASA Executive Director Patrick Ky said this weekend, quoted by Reuters. Last week it was the U.S. Federal Aviation Administration (FAA) that lifted the flight ban on the Boeing 737 MAX in the United States.
Merck announced the acquisition of privately held biopharmaceutical company OncoImmune for $425 million in cash.
Prosus reported a 29% increase in half-yearly earnings to $2.2 billion, and confirms the launch of the share buyback program unveiled at the end of October.
General Electric unions estimate that the group has cut 5,000 positions in France in five years.
Siegfried is thinking of going into biotechnology, according to its managing director Wolfgang Wienand interviewed by the magazine Finanz und Wirtschaft.
Elliott Advisors has submitted an offer to buy Aryzta at CHF 0.80 per share.
FDA approves Regeneron's antibody cocktail against coronavirus.
Californian online platform Wish wants to raise $25-30 billion by going public on Wall Street, according to the Financial Times.
The australian regulator opened an investigation into the malfunctions that affected the listings on ASX Limited a week ago.
Aluflexpack is investing €65 million in its Croatian plants.
Evergrande Property Services wants to enter Hong Kong.